🇺🇸 FDA
Pipeline program

CBP-307

CBP-307AU002

Phase 1 small_molecule completed

Quick answer

CBP-307 for Autoimmune Diseases is a Phase 1 program (small_molecule) at Connect Biopharma Holdings Ltd with 2 ClinicalTrials.gov record(s).

Program details

Company
Connect Biopharma Holdings Ltd
Indication
Autoimmune Diseases
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials